09:50:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-06-14 Ordinarie utdelning RAYTL 0.00 SEK
2024-06-13 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-04-22 Extra Bolagsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-11-24 Extra Bolagsstämma 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-03 Ordinarie utdelning RAYTL 0.00 SEK
2023-05-02 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-10-07 Extra Bolagsstämma 2022
2022-08-26 Kvartalsrapport 2022-Q2
2022-05-13 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning RAYTL 0.00 SEK
2022-04-18 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-27 Kvartalsrapport 2021-Q1
2021-04-20 Ordinarie utdelning RAYTL 0.00 SEK
2021-04-19 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-10-20 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-27 Kvartalsrapport 2020-Q1
2020-04-21 Ordinarie utdelning RAYTL 0.00 SEK
2020-04-20 Årsstämma 2020
2020-02-27 Bokslutskommuniké 2019
2019-10-21 Kvartalsrapport 2019-Q3
2019-04-23 Ordinarie utdelning RAYTL 0.00 SEK
2019-04-18 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriMedicinteknik
Raytelligence är verksamt inom forskning och innovation inom flera sektorer. Nyckelstrategin är att identifiera och slutföra en kombination med en verksamhet inom fordonsindustri, finansiella tjänster, livsmedelsteknik, hälsovård, spjutspetsteknologi och mediesektorer i Europa och Asien, även om bolaget förbehåller sig rätten att utöva en förvärvsmöjlighet i alla företag eller branscher. Huvudkontoret ligger i Stockholm.
2021-06-08 11:51:52

EaZense has been registered with the Medical Products Agency and certified under MDR. This means that the product is approved in accordance with the EU regulation on medical devices that ensures the safety and performance of medical devices.

EaZense has been CE marked according to previously applicable directives for medical devices, MDD. The EU's new Medical Devices Regulation (MDR) replaced the MDD in May 2021.

Like all medical technology companies with products on the European market, Raytelligence has had to adapt its operations to meet the new requirements for CE marking of the products.

"Our sensorsystem EaZense has been registered with the Medical Products Agency and certified under MDR. The MDR certification is important because it certifies that the product continues to meet the EU's essential health, safety and environmental requirements. The application was submitted on 26 May" says Klas Arvidson, CEO Raytelligence

About the EU regulationThe regulation updates the rules on which medical devices may be on the market, and how products are provided and used. The regulation improves patient safety by introducing stricter methods for assessment and monitoring in the market. It also contains rules for how medical technology companies conduct product evaluations within the EU. This ensures that unsafe and incompatible products and equipment do not end up on the market.

Questions are referred to:

Klas Arvidson, CEO Raytelligence

klas@raytelligence.com

+46 70 416 98 00

Raytelligence AB (publ)

Klammerdammsgatan 6

302 42 Halmstad

Sweden

The following documents can be retrieved from beQuoted
PR-2021-06-08-ENG.pdf

About Raytelligence AB (publ)

Raytelligence is a Swedish innovation company, based in Halmstad that offers products for monitoring vital parameters, ie breathing, heart rate and movement patterns, based on the company's own 60 GHz radar technology.